Video: How gene therapy could treat rare, incurable ‘day blindness’

Print Friendly, PDF & Email
Screen Shot at PM

[Editor’s note. Achromatopsia is a visual disorder sometimes referred to as “day blindness”.]

Imagine stepping out into a bright South Floriaya morning — and literally being so sensitive to light that it causes painful blindness. Imagine, too, being unable to discriminate between colors and slowly (and reluctantly) adapting to losing your sight.

For those suffering from achromatopsia (ACHM), a rare inherited condition with no cure, these situations are a reality. But now a clinical trial at four different U.S. sites, including University of Miami’s Bascom Palmer Eye Institute, is providing, quite literally, a ray of hope for those who suffer from this gene mutation.

The trial will evaluate a cutting-edge concept: gene therapy.

“For years, patients who had hereditary retinal diseases didn’t really have much hope,” said Dr. Byron Lam, a neuro-opthalmologist who specializes in hereditary retinal degenerations at UM’s Miller School of Medicine. “They were diagnosed, but there wasn’t anything anyone could do about it. Now there is hope. It’s the first time we can say, ‘We might be able to do something about this.’”

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Cutting-edge gene therapy provides hope for patients with inherited eye conditions

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

The U.S. averaged fewer than 40,000 new cases per day over the past week. That’s a 21% improvement over the ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists